Bayer mislaid a fifth of a marketplace value during one indicate Monday, after a German curative and rural organisation pronounced it had finished a late-stage exam for a anti-thrombotic drug asundexian due to a miss of efficacy.
News of a unsatisfactory hearing for a hoped-for blockbuster diagnosis came only dual days after Bayer’s XE:BAYN Monsanto section was systematic by a Missouri jury to compensate $1.56 billion to 3 former users of a group’s Roundup herbicide, that a litigants blamed for their cancer.
In…
